Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 245 followers
Latest posts
Last updated 3 days ago
Statement: Lilly has no affiliation with hims & hers
3 days ago
INDIANAPOLIS, April 1, 2025 – Eli Lilly and Company (NYSE: LLY) has...
Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels
5 days ago
In Phase 2 ALPACA results, lepodisiran significantly reduced levels of genetically inherited...
Lilly’s statement about the CHMP opinion issued for donanemab
7 days ago
INDIANAPOLIS, March 28, 2025 -- European Medicines Agency’s (EMA) Committee for Medicinal...
LillyDirect platform expands to facilitate access to Alzheimer's disease care
8 days ago
New tools to connect with independent in-person and telehealth providers specializing in...
Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
10 days ago
INDIANAPOLIS , March 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
27 days ago
Late-breaking results presented at AAD show 80% or more scalp hair coverage...
Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis
28 days ago
Among EBGLYSS Week 16 responders from the monotherapy trials, 50% achieved highest...
Lilly to participate in Leerink Partners Global Healthcare Conference
about 1 month ago
INDIANAPOLIS , Feb. 28, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor
about 1 month ago
The positive opinion is based on results from the Phase 3 BRUIN...
Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion
about 1 month ago
Company expects to begin building four more domestic manufacturing sites this year...
Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
about 1 month ago
New 7.5 mg and 10 mg Zepbound single-dose vials now available for...
Lilly to participate in TD Cowen's 45th Annual Health Care Conference
about 1 month ago
INDIANAPOLIS , Feb. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...